For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
In the latest session, 10x Genomics Inc (NASDAQ: TXG) closed at $16.29 up 0.87% from its previous closing price of $16.15. In other words, the price has increased by $0.87 from its previous closing price. On the day, 1.47 million shares were traded. TXG stock price reached its highest trading level at $16.35 during the session, while it also had its lowest trading level at $15.91.
Ratios:
For a deeper understanding of 10x Genomics Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.28 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 28.23. For the most recent quarter (mrq), Quick Ratio is recorded 4.06 and its Current Ratio is at 4.48. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.10.
On December 02, 2025, Morgan Stanley Downgraded its rating to Equal-Weight which previously was Overweight but kept the price unchanged to $20.
On September 11, 2025, Piper Sandler started tracking the stock assigning a Neutral rating and target price of $15.Piper Sandler initiated its Neutral rating on September 11, 2025, with a $15 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 24 ’25 when Taich Adam sold 11,888 shares for $19.00 per share. The transaction valued at 225,852 led to the insider holds 297,385 shares of the business.
Hindson Benjamin J. sold 8,283 shares of TXG for $157,363 on Nov 24 ’25. The insider now owns 432,605 shares after completing the transaction at $19.00 per share. On Nov 24 ’25, another insider, Saxonov Serge, who serves as the Chief Executive Officer of the company, sold 13,261 shares for $19.00 each. As a result, the insider received 251,936 and left with 1,021,556 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TXG now has a Market Capitalization of 2061549312 and an Enterprise Value of 1666450176. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.21 while its Price-to-Book (P/B) ratio in mrq is 2.63. Its current Enterprise Value per Revenue stands at 2.596 whereas that against EBITDA is -17.092.
Stock Price History:
The Beta on a monthly basis for TXG is 2.17, which has changed by 0.13812542 over the last 52 weeks, in comparison to a change of 0.17673707 over the same period for the S&P500. Over the past 52 weeks, TXG has reached a high of $20.34, while it has fallen to a 52-week low of $6.78. The 50-Day Moving Average of the stock is 2.54%, while the 200-Day Moving Average is calculated to be 32.49%.
Shares Statistics:
For the past three months, TXG has traded an average of 2.68M shares per day and 1871810 over the past ten days. A total of 116.46M shares are outstanding, with a floating share count of 112.05M. Insiders hold about 11.46% of the company’s shares, while institutions hold 96.95% stake in the company. Shares short for TXG as of 1765756800 were 15420723 with a Short Ratio of 5.75, compared to 1763078400 on 15501651. Therefore, it implies a Short% of Shares Outstanding of 15420723 and a Short% of Float of 19.36.
Earnings Estimates
. The current rating of 10x Genomics Inc (TXG) is the result of assessments by 3.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.18, with high estimates of -$0.08 and low estimates of -$0.28.
Analysts are recommending an EPS of between $0.46 and -$0.49 for the fiscal current year, implying an average EPS of -$0.05. EPS for the following year is -$0.41, with 3.0 analysts recommending between -$0.08 and -$0.9.
Revenue Estimates
A total of 15 analysts believe the company’s revenue will be $156.01M this quarter.It ranges from a high estimate of $157.2M to a low estimate of $154.1M. As of. The current estimate, 10x Genomics Inc’s year-ago sales were $165.02MFor the next quarter, 15 analysts are estimating revenue of $142.61M. There is a high estimate of $149.1M for the next quarter, whereas the lowest estimate is $135.85M.
A total of 15 analysts have provided revenue estimates for TXG’s current fiscal year. The highest revenue estimate was $634M, while the lowest revenue estimate was $630.9M, resulting in an average revenue estimate of $632.81M. In the same quarter a year ago, actual revenue was $610.78MBased on 16 analysts’ estimates, the company’s revenue will be $610.6M in the next fiscal year. The high estimate is $621.3M and the low estimate is $596M.
